Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

CARE-MS II investigators

Research output: Contribution to journalArticlepeer-review

986 Scopus citations

Fingerprint

Dive into the research topics of 'Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences